Sei Investments Co. Raises Position in Edwards Lifesciences Co. (NYSE:EW)

Sei Investments Co. boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 45.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 348,444 shares of the medical research company’s stock after buying an additional 108,821 shares during the quarter. Sei Investments Co.’s holdings in Edwards Lifesciences were worth $25,795,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC increased its holdings in shares of Edwards Lifesciences by 43.1% during the fourth quarter. Mizuho Securities USA LLC now owns 55,900 shares of the medical research company’s stock valued at $4,138,000 after acquiring an additional 16,838 shares in the last quarter. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $29,000. Northwest & Ethical Investments L.P. acquired a new position in Edwards Lifesciences during the 4th quarter valued at approximately $5,575,000. Teacher Retirement System of Texas raised its holdings in shares of Edwards Lifesciences by 780.6% in the fourth quarter. Teacher Retirement System of Texas now owns 35,533 shares of the medical research company’s stock worth $2,631,000 after buying an additional 31,498 shares during the last quarter. Finally, Royal London Asset Management Ltd. lifted its stake in shares of Edwards Lifesciences by 2.0% during the fourth quarter. Royal London Asset Management Ltd. now owns 251,205 shares of the medical research company’s stock worth $18,597,000 after buying an additional 5,027 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,553 shares of company stock worth $4,513,064. Insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on EW. Piper Sandler raised their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $71.12 on Thursday. The stock has a market capitalization of $41.81 billion, a P/E ratio of 10.20, a P/E/G ratio of 4.82 and a beta of 1.12. The company’s fifty day moving average price is $71.45 and its 200 day moving average price is $70.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.